Endonovo Therapeutics (OTCQB: ENDV) is an innovative biotechnology company developing a bioelectronic approach to regenerative medicine.
Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.
Alan Collier – Chairman & Chief Executive Officer
Mr. Collier has more than twenty years of experience in corporate finance, IP development, telecommunications and technology with a concentration in healthcare and technology over the last five years. Prior to his appointment as Endonovo’s CEO and chairman, Mr. Collier served as CEO and director of IP Resources International, Inc. where he was instrumental in developing a platform for for the licensing and acquisition of life science and technology companies.
Previously, Mr. Collier served as a Senior Managing Director at Mid-Market Securities, a FINRA-registered Broker-Dealer. Prior to joining Mid-Market Securities, Mr. Collier was a Managing Director at Mosaic capital and co-managed its Capital Markets Group. He was previously a Vice President at Corporate Capital Group and Managing Director and CEO of Greenbridge Capital Group.
Over the progression of his career, he has specialized in the development and financing of early stage, high growth, and acquisitive companies (public and private). He has structured, participated in, and completed numerous transactions including mergers and acquisitions, equity and debt placements, capital restructuring, joint venture development, and channel partner procurement. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Mr. Collier holds FINRA Series 7, 79, 63, and 24 Licenses.
Michael Scott Mann – President
Mr. Mann has over 30 years experience in merger and acquisitions and operational management. In 2008 Mr. Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics, Inc,. and led the company to become listed on the OTCBB in 2012.
From January 2003 to April, 2011, Mr. Mann was the Founder, President and Chief Executive Officer of U.S. Debt Settlement, Inc. (USDS), a Frankfurt listed company, where he implemented a growth by acquisition strategy successfully acquiring numerous companies.
From January 2002 to July 2003, Mr. Mann was the Chief Executive Officer of Shared Vision Capital, a boutique investment banking firm that assisted emerging companies with early seed capital and bridge loans. Earlier still, from October 1998 to December 2001, Mr. Mann was the Vice President of Investor Relations for JuriSearch.com, an online legal research platform. During his tenure with JuriSearch.com, Mr. Mann was directly responsible for funding the company’s growth and development. In addition, Mr. Mann founded Universal Pacific Communications, a privately owned telecommunications company. Under his leadership as President, Universal Pacific developed a fiber optic disaster recovery telecommunications network, designed for and successfully marketed to Fortune 1000 companies.
Leonard Makowka, M.D., Ph.D. – Chief Medical Officer
Over the past 30 years, Dr. Makowka has transitioned himself as a distinguished clinical and transplantation surgeon and medical researcher to a successful entrepreneur, advisor and board member in a wide range of industries. Since receiving his M.D. degree from the University of Toronto Medical School in 1977 and Ph.D. from the University of Toronto’s Department of Pathology in 1982, he has published over 400 articles and chapters in both clinical and basic scientific research.
Between 1989 and 1995, Dr. Makowka served as the Chairman of the Department of Surgery and Director of Transplantation Services at Cedars Sinai Medical Center in Los Angeles, California. During this time, he also served as Professor of Surgery at the UCLA School of Medicine. Dr. Makowka would later become Executive Director of the Comprehensive Liver Disease Center at St. Vincent’s Medical Center in Los Angeles, CA, where he created a multiple disciplinary approach to the treatment of liver disease. He is currently the active Chairman of the Corporate Advisory Board of the UCLA School of Nursing. Dr. Makowka has since retired from the active practice of medicine and has experienced a successful career in developing investment and business strategies for companies in the healthcare, life sciences, finance, and other industries.
Dr. Makowka has served on the board of directors for various private and publicly traded companies in the healthcare and life science industries. From 1998 to 2003 he served on the Board of Directors of Hollis Eden Pharmaceuticals, (NASDAQ: HEPH) and served on the Board of Directors for Kinmed, Inc., a privately held biotech company. As an entrepreneur, Dr. Makowka has worked with several companies in a wide range of industries. He was a founding consultant for Ivivi Technologies, Inc. (NASDAQ: IVVI), a publicly traded medical technology company focusing on designing, developing, and commercializing proprietary electrotherapeutic technologies. In addition, Dr. Makowka founded Trillenium Medical Imaging Inc., a company engaged in the novel healthcare application of proprietary infrared imaging.
As Endonovo Therapeutics’ Chief Medical Officer, Dr. Makowka will be responsible for developing the company’s scientific advisory board, overseeing the company’s clinical research activities and will serve as a liaison between the company and the medical community.
Donnie Rudd, Ph.D., D.Sc., D.D., J.D. – Chief Scientist & Director of Intellectual Property
Dr. Rudd began his career as a Chemical Engineer after graduating with a B. S. degree in Chemical Engineering from Texas A&M. His career then progressed into work as a successful Patent Attorney after obtaining his J.D. degree from Chicago-Kent College of Law. Over the course of 15 years of litigating cases as one of the principals of Rudd & Associates., he was admitted to over 14 courts and taught at 3 universities. Dr. Rudd has written 17 books and over 140 publications.
After a successful tenure and being recognized as “One of the top 5 attorneys in the United States”, he earned his Ph.D. in Bioscience and shifted his focus to stem cell and electromagnetic therapy research.
He joined Regenetech, Inc. in April 2002 as CEO and Corporate Secretary. In 2002 he became its Chief Scientist and Director of Intellectual Property. With patented licensing rights through an innovation from NASA, he lead in the research on the NASA licensed bioreactor. Subsequently, NASA researchers under Dr. Rudd’s guidance added TVEMF technology to the bioreactor. He has developed over 100 different patents and inventions focused on stem cell technology. In accordance with his patents and groundbreaking discoveries in stem cell research, he has become a NASA recognized inventor. For his patent and inventive work during his time at Regenetech, Inc., Dr. Rudd’s work received recognition from the Space Foundation after they inducted the Commercial Earth-Imaging Satellite and Intrifuge CellXpansion technology into the Space Technology Hall of Fame.
RECENT NEWS (Nov. 3, 2015)
Endonovo Therapeutics Developing Next-Generation Cell Therapy for Acute and Chronic Graft-Versus-Host Disease Using Cell-Enhancing Cytotronics Platform
Cytotronics™ Platform Allows for the Large-Scale Expansion and Enhancement of Immuno-Regulatory Stem Cells With Enhanced Biological and Therapeutic Properties
LOS ANGELES, CA--(Marketwired - Nov 3, 2015) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it is developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.
"We have taken our method of expanding a population of immune privileged stem cells from the human umbilical cord and combined it with our Cytotronics platform to create large quantities of optimized immuno-regulatory stem cells that can be used as an allogeneic, off-the-shelf therapy for the treatment of Graft-Versus-Host Disease," commented Endonovo Chief Scientist, Dr. Donnie Rudd.
Graft-Versus-Host Disease (GVHD) is a common complication following allogeneic tissue transplants, including bone marrow and cord blood transplants, wherein immune cells in the transplanted tissue (the graft) recognize the recipient (the host) as "foreign" and begin to attack the host's cells. Acute GVHD can result in significant damage to the liver, skin, mucosa and the gastrointestinal tract and is a major issue associated with high morbidity and mortality in transplants. The incidence of grade II-IV acute GVHD has been reported to vary between 20-85% in hematopoietic stem cell transplants.
Mesenchymal stem cells (MSCs) are captivating scientists around the world due to their therapeutic nature and ability to be harvested and cultivated quickly. These stem cells are being used to treat a wide variety of inflammatory diseases and have been suggested in the treatment of acute GVHD after bone marrow transplantation due to their ability to modulate the immune response.
Nonetheless, despite the promise of current MSC-based therapies, their poor engraftment and their short-term survival when transplanted are still major limitations to the effective therapeutic use of these stem cells.
"Our Cytotronics platform is particularly suited to address many of the issues that have plagued stem cell therapies that have recently failed, such as their loss of potency and self-renewal when expanded ex vivo, their poor engraftment and their limited ability to survive when transplanted," says Dr. Rudd.
Endonovo previously announced a method and composition process for the creation of a cell mixture from a portion of the human umbilical cord co-cultured with adipose-derived stem cells. The resulting cell mixture provides for a rich source of highly-proliferative, immunosuppressive and non-alloreactive cells that display neither of the major histocompatibility markers (HLA double negative). These immune privileged cells thus represent a significant source of cells for allogeneic mesenchymal cell-based therapies.
Endonovo Therapeutics has used this new technology to create a biologically potent, off-the-shelf, allogeneic treatment for Graft-Versus-Host disease and a wide-array of other conditions.
The Company believes that its development of next-generation cell therapies that have been enhanced ex vivo using its Cytotronics™ platform will be a major innovation in the regenerative medicine market, which is expected to increase from US$2.6 billion in 2012 to US$6.5 billion by 2019, according to Transparency Market Research.
"We are very excited to be a leader in the development of next-generation, ex vivo enhanced cells for regenerative medicine," stated Endonovo CEO, Alan Collier. "We have seen several stem cell therapies fail in clinical trials over the last couple of years, which points to a critical need for the development of methods to increase the biological and therapeutic properties of stem cells."
"We believe that enhancing the biological and therapeutic properties of stem cells using bioelectronics is the future of cell-based therapies," concluded Mr. Collier.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and enhancing the biological and therapeutic properties of cells for the development of next-generation cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108